Vaxess starts Phase 1 trial for H1 influenza vaccine patch - BioPharma-Reporter.com

Vaxess Technologies has launched a phase 1 trial for its H1 influenza vaccine patch: outlining its mission to increase access to vaccines via the shelf-stable, sustained-release patch.

The H1 influenza vaccine uses the Cambridge, Massachusetts companys MIMIX technology, with pre-clinical trials showing the system enhanced humoral and cellular immune responses in mice compared to va… [+1558 chars]

full article...